[ad_1]
According to a study by the World Health Organization, the drug Remdesivir from the American company Gilead Sciences does not have a substantial influence on the cure of Covid-19 patients.
What did the Financial times Thursday. This is the result of a clinical study. WHO initially declined to comment on the report, noting that the results of the study were not yet public.
In the large-scale study, the effect of four different drugs, in addition to remdesivir, the antimalarial drug hydroxychloroquine, the HIV drug lopinavir / ritonavir, and the active ingredient interferon, was tested in more than 11,200 patients in more than 30 countries.
According to the WHO, the drugs had little or no effect on mortality or length of hospital stay of the patient. Remdesivir is one of the first drugs to be used to treat corona patients. The president of the United States, Donald Trump, also received it recently after his infection.
An American study only confirmed its effectiveness in October
The results of the WHO study contrast with an American study with 1,062 patients, which was carried out earlier this month in the renowned New England Journal of Medicine had been published. Thereafter, Remdesivir shortened the recovery time of Covid 19 patients by five days compared to those who were ill and did not receive the drug.
Among other things, US President Donald Trump was treated with remdesivir after being infected with the corona virus.
The WHO results contradict studies showing the clinical benefits of remdesivir, Gilead said. “We are concerned that the data from this global study has not undergone the rigorous review necessary to allow for constructive scientific discussion, especially given the limitations of the study design.”
WHO chief scientist Soumya Swaminathan had stated this week that tests with hydroxychloroquine and lopinavir / ritonavir had been suspended in June because they were ineffective.
Remdesivir received emergency approval from the US FDA in May and has since been approved for the treatment of Covid-19 patients in other countries. It had also received conditional approval in Europe. Gilead originally developed the drug to treat diseases caused by the Ebola, Marburg, Mers and Sars viruses.
